It is important to recognize that biologics are heterogenous and mitigating heterogeneity risks for quality is crucial when developing biosimilars – products that are highly similar to an approved biological product. Biologics are made by or derived from living organisms, and therefore, they are structurally complex and heterogenous compared to small-molecule drugs

To provide a deeper understanding of our quality-focused biosimilar development, Jae-woong Hwang, Cell line Development Group Leader at Samsung Bioepis, highlighted how we have ensured quality during the whole manufacturing process development and key steps to lower heterogeneity risks, presented virtually at the annual the World Biosimilar Congress (WBC) on March 31.

Watch key highlights of the presentation to learn more.